HABP2 and non-small cell lung carcinoma: Furthermore, PHBP mRNA levels were found to be upregulated in non-small-cell lung cancer (NSCLC) [104], while a downregulation and loss of function mutation of HABP2 were seen in head and neck squamous cell carcinoma [105] and thyroid carcinoma [106], separately.